Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

Instead of just assuming a patient is refractory because they’ve relapsed, Gisselbrecht’s team wanted a more precise definition.

In collaboration with several companies and cancer centers, Gisselbrecht’s team determined several types of refractory patients.

By defining different groups of relapsed patients, prognostic factors can be determined for specific populations, says Gisselbrecht.

Conference

® Conference page includes a listing of all conferences covered by 

, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.


European Hematology Association Congress


​Christian Gisselbrecht, MD, a Professor of Haematology in the Haemato-Oncology Department of Hôpital Saint-Louis, at Diderot University, Paris, discusses stratifying refractory disease in aggressive diffuse large b-cell lymphoma (DLBCL).

Dr. Christian Gisselbrecht on Defining Refractory Disease in DLBCL